B. Riley Expects Reduced Earnings for Viking Therapeutics

Viking Therapeutics, Inc. (NASDAQ:VKTX) – B. Riley dropped their Q2 2025 earnings estimates for shares of Viking Therapeutics in a report released on Thursday, April 24th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings of ($0.43) per share for the quarter, down from their previous estimate of ($0.33). B. Riley currently has a “Buy” rating and a $96.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.41) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($2.92) EPS.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) earnings per share.

A number of other equities research analysts have also recently issued reports on VKTX. Cantor Fitzgerald assumed coverage on shares of Viking Therapeutics in a research report on Monday. They issued an “overweight” rating and a $104.00 target price for the company. Piper Sandler cut their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating for the company in a report on Thursday, February 6th. Maxim Group lowered their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, February 7th. The Goldman Sachs Group started coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, Morgan Stanley reduced their price target on Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.15.

Viking Therapeutics Price Performance

VKTX opened at $27.94 on Monday. The company has a market capitalization of $3.14 billion, a PE ratio of -27.94 and a beta of 0.84. The business has a fifty day simple moving average of $26.27 and a 200 day simple moving average of $39.98. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86.

Insider Transactions at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now directly owns 1,240 shares in the company, valued at $29,946. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Viking Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. World Investment Advisors LLC bought a new position in shares of Viking Therapeutics in the 3rd quarter valued at $240,000. Tidal Investments LLC increased its holdings in Viking Therapeutics by 296.8% in the 3rd quarter. Tidal Investments LLC now owns 15,190 shares of the biotechnology company’s stock worth $962,000 after purchasing an additional 11,362 shares in the last quarter. Principal Financial Group Inc. raised its position in Viking Therapeutics by 29.9% in the third quarter. Principal Financial Group Inc. now owns 593,528 shares of the biotechnology company’s stock valued at $37,576,000 after purchasing an additional 136,729 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Viking Therapeutics during the fourth quarter valued at about $92,000. Finally, Salem Investment Counselors Inc. grew its holdings in shares of Viking Therapeutics by 557.8% during the fourth quarter. Salem Investment Counselors Inc. now owns 3,289 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 2,789 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.